| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
11,270,000 |
| Market
Cap: |
290.65(M) |
| Last
Volume: |
197,427 |
Avg
Vol: |
196,888 |
| 52
Week Range: |
$13.82 - $26.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
5,250 |
117,800 |
| Total Buy Value |
$0 |
$0 |
$74,754 |
$2,088,813 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
5 |
21 |
| Total Shares Sold |
0 |
0 |
0 |
27,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2012-12-31 |
5 |
A |
$2.53 |
$5,591 |
I/I |
2,214 |
4,422 |
|
- |
|
| Kurland Fred |
CFO & VP Finance |
• – – |
2012-12-31 |
5 |
A |
$2.53 |
$11,250 |
I/I |
4,455 |
17,396 |
|
- |
|
| Varian John |
Director and CEO |
• • – |
2012-12-31 |
5 |
A |
$2.53 |
$11,250 |
I/I |
4,455 |
13,797 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2012-12-31 |
4 |
OE |
$2.28 |
$1,899 |
D/D |
833 |
2,036 |
|
- |
|
| Kurland Fred |
CFO & VP Finance |
• – – |
2012-11-14 |
4 |
S |
$2.56 |
$23,310 |
D/D |
(9,111) |
13,485 |
|
- |
|
| Scannon Patrick J Md Phd |
Executive Vice President |
• • – |
2012-11-14 |
4 |
S |
$2.56 |
$22,445 |
D/D |
(8,773) |
17,448 |
|
- |
|
| Varian John |
Director and CEO |
• • – |
2012-11-14 |
4 |
S |
$2.56 |
$103,807 |
D/D |
(40,587) |
60,079 |
|
- |
|
| Bowes William K Jr |
Director |
– • – |
2012-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,499 |
5,570 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2012-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,499 |
4,499 |
|
- |
|
| Kurland Fred |
CFO & VP Finance |
• – – |
2012-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,596 |
22,596 |
|
- |
|
| Walbert Timothy P |
Director |
– • – |
2012-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,499 |
4,499 |
|
- |
|
| Scannon Patrick J Md Phd |
Executive Vice President |
• • – |
2012-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,653 |
26,221 |
|
- |
|
| Varian John |
Director and CEO |
• • – |
2012-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,666 |
100,666 |
|
- |
|
| Van Ness W Denman |
Director |
– • – |
2012-11-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,876 |
6,876 |
|
- |
|
| Baker Felix |
Director |
– • • |
2012-10-29 |
4 |
B |
$3.00 |
$14,167,998 |
I/I |
4,722,666 |
463,839 |
2.25 |
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2012-09-28 |
4 |
OE |
$3.51 |
$1,900 |
D/D |
542 |
1,203 |
|
- |
|
| 14159, L.p. |
Director |
– • – |
2012-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
360,231 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • – |
2012-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,606,093 |
|
- |
|
| 667, L.p. |
Director |
– • – |
2012-07-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,585,591 |
|
- |
|
| Neu Kelvin |
Director |
– • – |
2012-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
16,800 |
16,800 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2012-06-29 |
4 |
OE |
$2.83 |
$1,871 |
D/D |
661 |
661 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2012-06-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,887 |
0 |
|
- |
|
| Rubin Paul D |
VP Clinical Dev. & CMO |
• – – |
2012-03-30 |
4 |
OE |
$2.63 |
$3,234 |
D/D |
1,229 |
3,887 |
|
- |
|
| Baker Julian |
10% Owner |
– – • |
2012-03-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,585,591 |
|
- |
|
| Baker Julian |
10% Owner |
– – • |
2012-03-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
13,606,093 |
|
- |
|
597 Records found
|
|
Page 20 of 24 |
|
|
0.55 (2.18%) 
